Rival antirheumatics Simponi and Cimzia receive EU positive opinions
This article was originally published in Scrip
Two competing anti-TNF therapies, Centocor (Johnson & Johnson) and Schering-Plough's Simponi (golimumab) and UCB's Cimzia (certolizumab pegol), have received positive endorsements for approval from the EU's CHMP.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.